文献速递神经肿瘤功能神经外科

胶质瘤清醒手术最初5年不良事件与功能状态的标准化报告:一项基于人群的单中心连续病例系列

Standardized reporting of adverse events and functional status from the first 5 years of awake surgery for gliomas: a population-based single-institution consecutive series.
PubMed 文献 · Acta Neurochir (Wien) · 2022-04-14

该研究回顾性分析了单中心开展清醒手术最初5年(2015年2月至2020年2月)连续42例胶质瘤患者,按Landriel-Ibanez分类报告不良事件,30天并发症率为59%(25例),其中I级45%(19例)、II级7%(3例)、III级7%(3例); transient神经功能障碍36%(15例),永久性26%(11例)。3个月随访时全队列Karnofsky功能评分≥80,中位切除程度87%,全切除26%(11例);早期组与后期组各21例在手术时间、肿瘤切除量及长期神经功能障碍发生率上无统计学显著差异。

要点

  • 30天并发症率59%(25例),其中I级45%(19例)、II级7%(3例)、III级7%(3例)。
  • transient神经功能障碍36%(15例),永久性神经功能障碍26%(11例)。
  • 3个月随访全队列Karnofsky功能评分≥80,中位切除程度87%,全切除26%(11例)。

核心结论

  • 单中心5年学习期内清醒手术治疗胶质瘤的严重不良事件率和功能结局与文献相似,未发现明显学习曲线困难。
  • 与文献比较因并发症报告非标准化而存在缺陷,凸显清醒开颅术后不良事件标准化报告的需求。

研究设计与样本

  • 回顾性连续病例系列,纳入本中心引入清醒手术最初5年(2015年2月至2020年2月)内接受清醒手术的全部胶质瘤患者,共42例。
  • 中位年龄38岁(范围18-66岁),女性13例(31%)。
  • 按Landriel-Ibanez神经外科并发症分类评估不良事件,神经功能障碍分为 transient与永久性。
  • 将患者分为早期组(前21例)与后期组(后21例)以分析学习曲线。

主要发现

  • 30天总并发症率59%(25例),其中I级45%(19例)、II级7%(3例)、III级7%(3例)。
  • transient神经功能障碍36%(15例),永久性神经功能障碍26%(11例)。
  • 3个月随访时全队列Karnofsky功能评分≥80。
  • 中位切除程度87%,全切除26%(11例)。
  • 早期组与后期组在手术时间、肿瘤切除量及长期术后神经功能障碍发生率上无统计学显著差异;无因癫痫发作中止清醒手术。

局限性

  • 与文献比较受限于既往研究对胶质瘤清醒开颅术后不良事件的报告方式多样且不系统。
  • 该比较因并发症报告非标准化而存在缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report our experience and investigate frequencies of adverse events and functional status from the first 5 years of performing awake surgery for gliomas in a single-center population-based setting. METHODS: We conducted a review of all patients with a glioma treated with awake surgery during the first 5 years following introduction of awake surgery at our center (February 2015 to February 2020). We assessed functional and radiological outcome, with adverse events classified according to the Landriel-Ibanez classification for neurosurgical complications, while neurological deficits were further subdivided into transient vs permanent. We sought to analyze our initial results and learning curve, as well as compare our results with literature. RESULTS: Forty-two patients were included. The median age was 38 years (range 18-66) and 13 (31%) were female. The indication for awake surgery was a presumed glioma in or near an eloquent area. The overall 30-day complication rate was 25 (59%), with 19 (45%) grade I complications, 3 (7%) grade II complications, and 3 (7%) grade III complications. Fifteen patients (36%) experienced transient neurological deficits, and 11 (26%) permanent neurological deficits. At 3-month follow-up, the Karnofsky Performance Score was 80 or higher for the entire cohort. The median extent of resection was 87%, with GTR achieved in 11 (26%). In search of potential learning curve difficulties, patients were divided into the 21 patients treated first (Early Group) versus the remaining 21 patients treated later (Late Group); no statistically significant difference in operating time, amount of tumor removed, or incidence of long-term postoperative neurological deficit was identified between groups. No awake surgery was aborted due to seizures. Comparison to the literature was limited by the diverse and unsystematic way in which previous studies have reported adverse events after awake craniotomy for gliomas. CONCLUSION: We provide a standardized report of adverse events and functional status following awake surgery for glioma during a single-center 5-year learning period, with similar rates of severe adverse events and functional outcome compared to literature without concerns of substantial learning curve difficulties. However, this comparison was flawed by non-standardized reporting of complications, highlighting a demand for more standardized reporting of adverse events after awake craniotomies.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Jensdottir M, Beniaminov S, Jakola AS, et al. Standardized reporting of adverse events and functional status from the first 5 years of awake surgery for gliomas: a population-based single-institution consecutive series. Acta Neurochir (Wien). 2022. PMID: 35420374. doi:10.1007/s00701-022-05191-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。